Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018161279) USE OF MTOR INHIBITOR AND CHLOROQUINE FOR TREATING CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/161279 International Application No.: PCT/CN2017/075987
Publication Date: 13.09.2018 International Filing Date: 08.03.2017
IPC:
A61K 31/436 (2006.01) ,A61K 31/4706 (2006.01) ,A61K 31/56 (2006.01) ,A61K 39/395 (2006.01) ,A61K 45/00 (2006.01) ,A61P 35/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
436
the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4706
4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
JOHNPRO BIOTECH INC. [CN/CN]; 2F., No.118 Hougang St., Shilin Dist. Taipei City, Taiwan 111, CN
Inventors:
CHI, Kwan-Hwa; CN
WANG, Yu-Shan; CN
HUANG, Yi-Chun; CN
CHIANG, Hsin-Chien; CN
Agent:
CHINA ZHENGHE INTELLECTUAL PROPERTY AGENCY; Unit C7, Floor 17, Block 2, Xihuan Plaza No. 1 Xizhimenwai Street, Xicheng District Beijing 100044, CN
Priority Data:
Title (EN) USE OF MTOR INHIBITOR AND CHLOROQUINE FOR TREATING CANCER
(FR) UTILISATION D'UN INHIBITEUR DE MTOR ET DE CHLOROQUINE POUR LE TRAITEMENT DU CANCER
Abstract:
(EN) Disclosed herein are uses of a mammalian target of rapamycin (mTOR) inhibitor and chloroquine or analogue thereof in the manufacture of a medicament for treating cancer patients who are not responsive to a hormone therapy and an immunotherapy. In particular, the medicament is used during the hormone therapy and the immunotherapy to sensitize the patients to the hormone therapy and the immunotherapy.
(FR) L'invention concerne des utilisations d'une cible mammifère d'inhibiteur de rapamycine (mTOR) et de chloroquine ou d'un analogue de celle-ci dans la fabrication d'un médicament pour le traitement de patients atteints de cancer qui ne réagissent pas à une hormonothérapie et à une immunothérapie. En particulier, le médicament est utilisé pendant l'hormonothérapie et l'immunothérapie pour sensibiliser les patients à ladite hormonothérapie et immunothérapie.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)